ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC

Xiuning Le; Monique B. Nilsson; Jacqulyne P. Robichaux; John V. Heymach

doi:10.1016/j.ccell.2021.07.017

ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC

Xiuning Le, Monique B. Nilsson, Jacqulyne P. Robichaux, John V. Heymach

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen in patients with brain metastases and EGFR L858R mutation. This provides further evidence for the tailored use of VEGF/EGFR combinations.

Original language	English (US)
Pages (from-to)	1178-1180
Number of pages	3
Journal	Cancer cell
Volume	39
Issue number	9
DOIs	https://doi.org/10.1016/j.ccell.2021.07.017
State	Published - Sep 13 2021

ASJC Scopus subject areas

Oncology
Cell Biology
Cancer Research

Access to Document

10.1016/j.ccell.2021.07.017

Cite this

@article{b5f7377a3da042b590b311431b40cbeb,

title = "ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC",

abstract = "The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen in patients with brain metastases and EGFR L858R mutation. This provides further evidence for the tailored use of VEGF/EGFR combinations.",

author = "Xiuning Le and Nilsson, {Monique B.} and Robichaux, {Jacqulyne P.} and Heymach, {John V.}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = sep,

day = "13",

doi = "10.1016/j.ccell.2021.07.017",

language = "English (US)",

volume = "39",

pages = "1178--1180",

journal = "Cancer cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "9",

}

TY - JOUR

T1 - ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC

AU - Le, Xiuning

AU - Nilsson, Monique B.

AU - Robichaux, Jacqulyne P.

AU - Heymach, John V.

PY - 2021/9/13

Y1 - 2021/9/13

N2 - The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen in patients with brain metastases and EGFR L858R mutation. This provides further evidence for the tailored use of VEGF/EGFR combinations.

AB - The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen in patients with brain metastases and EGFR L858R mutation. This provides further evidence for the tailored use of VEGF/EGFR combinations.

UR - http://www.scopus.com/inward/record.url?scp=85116957670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85116957670&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2021.07.017

DO - 10.1016/j.ccell.2021.07.017

M3 - Article

C2 - 34388379

AN - SCOPUS:85116957670

SN - 1535-6108

VL - 39

SP - 1178

EP - 1180

JO - Cancer cell

JF - Cancer cell

IS - 9

ER -

ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this